Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Cancer Type/Condition:  Islet cell tumor
Results 1-20 of 20 for your search:
Start Over
Temozolomide and Pazopanib Hydrochloride in Treating Patients with Advanced Pancreatic Neuroendocrine Tumors That Cannot Be Removed by Surgery
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: NU 11I03, NCI-2011-02939, NCT01465659
VEGFR/PDGFR Dual Kinase Inhibitor X-82 and Everolimus for Treating Patients with Pancreatic Neuroendocrine Tumors
Phase: Phase II, Phase I
Type: Treatment
Age: 18 andover
Trial IDs: 201303150, NCI-2013-00641, NCT01784861
Bevacizumab, Capecitabine, and Temozolomide in Treating Patients with Pancreatic Neuroendocrine Tumors That Are Metastatic or Cannot Be Removed by Surgery
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: NET0012, NCI-2011-03497, 22412, END0012, SU-10282011-8571, NCT01525082
Temozolomide with or without Capecitabine in Treating Patients with Advanced Pancreatic Neuroendocrine Tumors
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: E2211, NCI-2012-02007, NCT01824875
Gallium Ga 68-DOTATATE PET/CT in Diagnosing Patients with Primary or Metastatic Gastrointestinal or Pancreatic Neuroendocrine Tumors
Phase: Phase II
Type: Diagnostic
Age: 18 and over
Trial IDs: 13-C-0193, NCI-2014-02318, 335154, NCT01967537
Mutation-Targeted Therapy with Sunitinib Malate or Everolimus in Treating Patients with Advanced Neuroendocrine Tumors of the Gastrointestinal Tract or Pancreas
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 15-C-0040, NCI-2015-00091, 14-C-0000, 150040, 339636, P141605, NCT02315625
Gallium Ga 68-DOTATATE PET/CT in Diagnosing Patients With Somatostatin-Receptor Positive Tumors
Phase: Phase II
Type: Biomarker/Laboratory analysis, Diagnostic
Age: 19 and over
Trial IDs: NET0017, NCI-2014-01016, 26988, NCI-2014-00101, NCT01980732
Safety and Pharmacology of SNX-5422 Plus Everolimus in Subjects With Neuroendocrine Tumors
Phase: Phase I
Type: Treatment
Age: 18 and over
Trial IDs: SNX5422-CLN-009, NCI-2014-02577, NCT02063958
MLN0128 and Ziv-Aflibercept in Treating Patients with Recurrent Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 2013-0665, NCI-2014-01107, 9585, NCT02159989
Follow Up Protocol for Subjects Previously Enrolled in NCI Surgery Branch Studies
Phase: No phase specified
Type: Natural history/Epidemiology
Age: 16 and over
Trial IDs: 090161, 09-C-0161, NCT00923026
Prospective Comprehensive Molecular Analysis of Endocrine Neoplasms
Phase: No phase specified
Type: Biomarker/Laboratory analysis
Age: 7 and over
Trial IDs: 090242, 09-C-0242, NCT01005654
Natural History of Imaging Pancreatic Lesions in Patients With Von Hippel-Lindau Syndrome
Phase: No phase specified
Type: Natural history/Epidemiology
Age: 12 and over
Trial IDs: 03-C-0145, NCI-2013-02040, 030145, NCT01444950, NCT00062166
Molecular Analysis in Tissue Samples From Patients With Advanced or Metastatic Neuroendocrine Tumors
Phase: No phase specified
Type: Biomarker/Laboratory analysis, Natural history/Epidemiology
Age: 18 and over
Trial IDs: CGI-061, NCI-2013-01950, NCT02092714
Clinical Manifestations and Genetic Defects in Identifying Disease Causality in Samples From Patients with Heritable Urologic Malignant Disorders
Phase: No phase specified
Type: Genetics, Natural history/Epidemiology
Age: Not specified
Trial IDs: 89-C-0086, NCI-2013-02066, 890086, NCT00019617, NCT00001238
18F-MFBG PET/CT in Imaging Patients with Neuroendocrine Malignancies
Phase: No phase specified
Type: Biomarker/Laboratory analysis, Diagnostic
Age: 5 and over
Trial IDs: 14-138, NCI-2015-00234, NCT02348749
Gallium Ga 68-edotreotide PET/CT in Diagnosing Patients with Neuroendocrine Tumors
Phase: No phase specified
Type: Diagnostic
Age: Not specified
Trial IDs: 14-226, NCI-2015-00286, NCT02358018
Assessing Quality of Life in Patients with Refractory Malignant Ascites Undergoing Peritoneal-Venous Shunt
Phase: No phase specified
Type: Biomarker/Laboratory analysis, Supportive care
Age: 18 and over
Trial IDs: UPCC 26813, NCI-2015-01009, 819053, NCT02477657
Start Over